Newsfeed

Bei diesem Bereich handelt es sich um eine mögliche Darstellungsform der Integration von Nachrichtenquellen mit Bezug zu börsennotierten Unternehmen.
Als Präsentationsebene fungiert ein Template, dass an Kurznachrichtenservices angelehnt ist, bei dem sich Nutzer einen schnellen Überblick über aktuelle Nachrichten verschaffen können. Die Detailansichten ermöglichen bei Interesse weitergehende Recherchen.

Dieser Newsfeed ist eine Zusammenstellung aktueller Nachrichten, die aus Direktanbindungen von TopTier NewsWire-Services mit Bezug zu börsennotierten Unternehmen stammen. Dieser Feed hier dient ausschließlich Demonstrationszwecken. Sektoren-spezifische Nachrichten, Public Relations sowie Produktinformationen können über die GICS Portale > Bereich Sektor-Intelligence abgerufen werden.

US0029421007
Filter zurücksetzen
Do you already know our new terminal view? Click here.
FIGI: BBG01223DLB2
AARD
Aardvark Therapeutics Inc
GICS: Health Care · SECTOR: EQTY · SUB-SECTOR: Software - Application · THEMEFOLIO: $HLTH
NAME
Aardvark Therapeutics Inc
ISIN
US0029421007
TICKER
AARD
MIC
XNAS
REUTERS
AARD.OQ
BLOOMBERG
AARD US
Sa., 19.09.2026       Aardvark Therapeutics
US0029421007

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Aardvark To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in (a) Aardvark common stock pursuant and/or traceable to the Offering Documents (defined below) issued in connection with the Compan...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 18.09.2026       Aardvark Therapeutics
US0029421007

San Francisco, California--(Newsfile Corp. - September 18, 2026) - Hagens Berman Sobol Shapiro LLP, a national shareholder rights firm, notifies investors in Aardvark Therapeutics, Inc. (NASDAQ: AARD) of a pending securities class action lawsuit.Investors who purchased or acquired Aardvark common stock pursuant and/or traceable to the offering docu...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 18.09.2026       Aardvark Therapeutics
US0029421007

Levi & Korsinsky, LLP alerts investors in Aardvark Therapeutics, Inc. (NASDAQ: AARD) that a securities class action has been filed on behalf of shareholders who purchased or acquired securities between February 13, 2025 and May 14, 2026, and/or pursuant to the Company's February 2025 initial public offering. Find out if you may be eligible to r...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 17.09.2026       Aardvark Therapeutics
US0029421007

San Diego, California--(Newsfile Corp. - September 17, 2026) - Shareholder rights law firm Robbins LLP reminds investors that a class action was filed on behalf of all persons and entities who purchased or otherwise acquired Aardvark Therapeutics, Inc. (NASDAQ: AARD) (a) common stock pursuant to the Company's February 13, 2025 initial public offeri...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 17.09.2026       Aardvark Therapeutics
US0029421007

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses in Aardvark to Contact Him Directly to Discuss Their OptionsNew York, New York--(Newsfile Corp. - September 17, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors of the October 13, 2026 deadli...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 17.09.2026       Aardvark Therapeutics
US0029421007

Dated chronology: from a $16.00 IPO in February 2025 to a Phase 3 pause and a full FDA clinical hold, a securities class action alleges Aardvark Therapeutics' ARD-101 safety representations unraveled while AARD shares fell to $4.57.NEW YORK, Sept. 17, 2026 /PRNewswire/ -- SueWallSt encourages investors who suffered losses in Aardvark Therapeutics,...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 17.09.2026       Aardvark Therapeutics
US0029421007

NEW YORK, Sept. 17, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Aardvark Therapeutics, Inc. ("Aardvark" or the "Company") (NASDAQ: AARD) and certain officers and directors. The class action, filed in the United States District Court for the Southern District of California, and docketed under 26-c...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 17.09.2026       Aardvark Therapeutics
US0029421007

NEW YORK, Sept. 16, 2026 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of Aardvark Therapeutics, Inc. (NASDAQ: AARD): (i) common stock pursuant and/or traceable to the registration statement and prospectus (collectively, the "Registration Statement") issued in connection with Aardvark's February 13, 2025 ini...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 16.09.2026       Aardvark Therapeutics
US0029421007

A securities class action alleges Aardvark Therapeutics overstated the clinical, regulatory, and commercial prospects of ARD-101 while representing the drug as nearly free of systemic exposure, before a trial pause and FDA clinical hold erased most of the stock's value.NEW YORK, Sept. 16, 2026 /PRNewswire/ -- "Investors deserve transparency about...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 16.09.2026       Aardvark Therapeutics
US0029421007

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Aardvark To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in (a) Aardvark common stock pursuant and/or traceable to the Offering Documents (defined below) issued in connection with the Compan...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Di., 15.09.2026       Aardvark Therapeutics
US0029421007

SAN FRANCISCO, Sept. 15, 2026 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP, a national shareholder rights firm, notifies investors in Aardvark Therapeutics, Inc. (NASDAQ: AARD) of a pending securities class action lawsuit. Investors who purchased or acquired Aardvark common stock...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 14.09.2026       Aardvark Therapeutics
US0029421007

LOS ANGELES, Sept. 14, 2026 /PRNewswire/ -- Glancy Prongay Wolke & Rotter LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against Aardvark Therapeutics, Inc. IF YOU SUFFERED A LOSS ON YOUR AARDVARK THERAPEUTICS, INC. INV...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 14.09.2026       Aardvark Therapeutics
US0029421007

SAN FRANCISCO, Sept. 14, 2026 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP, a national shareholder rights firm, notifies investors in Aardvark Therapeutics, Inc. (NASDAQ: AARD) of a pending securities class action lawsuit. Investors who purchased or acquired Aardvark common stock...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 14.09.2026       Aardvark Therapeutics
US0029421007

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Aardvark To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in (a) Aardvark common stock pursuant and/or traceable to the Offering Documents (defined below) issued in connection with the Compan...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Sa., 12.09.2026       Aardvark Therapeutics
US0029421007

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Aardvark To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in (a) Aardvark common stock pursuant and/or traceable to the Offering Documents (defined below) issued in connection with the Compan...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 11.09.2026       Aardvark Therapeutics
US0029421007

San Francisco, California--(Newsfile Corp. - September 11, 2026) - Hagens Berman Sobol Shapiro LLP, a national shareholder rights firm, notifies investors in Aardvark Therapeutics, Inc. (NASDAQ: AARD) of a pending securities class action lawsuit.Investors who purchased or acquired Aardvark common stock pursuant and/or traceable to the offering docu...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 11.09.2026       Aardvark Therapeutics
US0029421007

BENSALEM, Pa., Sept. 11, 2026 /PRNewswire/ -- The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Aardvark Therapeutics, Inc. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN AARDVARK THERAPEUTICS, INC. (AARD), CONTACT THE LAW OFFICES OF HOWARD...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 11.09.2026       Aardvark Therapeutics
US0029421007

New York, New York--(Newsfile Corp. - September 11, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Aardvark Therapeutics, Inc. (NASDAQ: AARD) and certain of its officers.This lawsuit seeks to recover damages against Defendants for alleged...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 11.09.2026       Aardvark Therapeutics
US0029421007

NEW YORK, Sept. 11, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of Aardvark Therapeutics, Inc. (NASDAQ: AARD): (i) common stock pursuant and/or traceable to the registration statement and prospectus (collectively, the "Registration Statement") issued in connection with Aardvark's February 13, 202...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 10.09.2026       Aardvark Therapeutics
US0029421007

NEW YORK, Sept. 10, 2026 /PRNewswire/ -- Moore Law, PLLC, a shareholder litigation law firm located on Wall Street, is investigating potential claims against the officers and directors of Aardvark Therapeutics, Inc. (NASDAQ: AARD): Aardvark Therapeutics, Inc. (NASDAQ: AARD) sharehold...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Do., 10.09.2026       Aardvark Therapeutics
US0029421007

LOS ANGELES, Sept. 10, 2026 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to Aardvark Therapeutics, Inc. (AARD) have opportunity to lead the securities fraud class action lawsuit. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN AARDVARK T...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 10.09.2026       Aardvark Therapeutics
US0029421007

SAN FRANCISCO, Sept. 10, 2026 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP, a national shareholder rights firm, notifies investors in Aardvark Therapeutics, Inc. (NASDAQ: AARD) of a pending securities class action lawsuit. Investors who purchased or acquired Aardvark common stock...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 10.09.2026       Aardvark Therapeutics
US0029421007

New York, New York--(Newsfile Corp. - September 10, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Aardvark Therapeutics, Inc. (NASDAQ: AARD) and certain of its officers.This lawsuit seeks to recover damages against Defendants for alleged...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 10.09.2026       Aardvark Therapeutics
US0029421007

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses in Aardvark to Contact Him Directly to Discuss Their OptionsNew York, New York--(Newsfile Corp. - September 10, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors of the October 13, 2026 deadli...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 10.09.2026       Aardvark Therapeutics
US0029421007

NEW YORK, Sept. 10, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Aardvark Therapeutics, Inc. ("Aardvark" or the "Company") (NASDAQ: AARD) and certain officers and directors.   The class action, filed in the United States District Court for the Southern District of California, and docketed under 26...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 10.09.2026       Aardvark Therapeutics
US0029421007

Sections 11 and 15 of the Securities Act impose liability for registration statements containing untrue statements of material fact. A securities class action alleges Aardvark Therapeutics' IPO paperwork described ARD-101 as "99% restricted to the gut" with "no serious adverse events" while omitting safety risks that later drew an FDA clinical hol...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 09.09.2026       Aardvark Therapeutics
US0029421007

SAN FRANCISCO, Sept. 9, 2026 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP, a national shareholder rights firm, notifies investors in Aardvark Therapeutics, Inc. (NASDAQ: AARD) of a pending securities class action lawsuit. Investors who purchased or acquired Aardvark common stock p...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 09.09.2026       Aardvark Therapeutics
US0029421007

New York, New York--(Newsfile Corp. - September 9, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Aardvark Therapeutics, Inc. (NASDAQ: AARD) and certain of its officers.This lawsuit seeks to recover damages against Defendants for alleged...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 09.09.2026       Aardvark Therapeutics
US0029421007

A securities class action alleges Aardvark Therapeutics' SEC filings warned about clinical risk in generic terms while describing ARD-101 as "99% restricted to the gut" with "no serious adverse events" and "no renal or hepatic safety limitations" — language the complaint contends did not disclose the specific cardiac safety issues that later drew...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 09.09.2026       Aardvark Therapeutics
US0029421007

New York, New York--(Newsfile Corp. - September 8, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of Aardvark Therapeutics, Inc. (NASDAQ: AARD): (i) common stock pursuant and/or traceable to the registration statement and prospectus (collectively, the "Registration Statement") issued in connection with Aardvark's...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 09.09.2026       Aardvark Therapeutics
US0029421007

San Francisco, California--(Newsfile Corp. - September 8, 2026) - Hagens Berman Sobol Shapiro LLP, a national shareholder rights firm, notifies investors in Aardvark Therapeutics, Inc. (NASDAQ: AARD) of a pending securities class action lawsuit.Investors who purchased or acquired Aardvark common stock pursuant and/or traceable to the offering docum...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 08.09.2026       Aardvark Therapeutics
US0029421007

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Aardvark To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in (a) Aardvark common stock pursuant and/or traceable to the Offering Documents (defined below) issued in connection with the Compan...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 07.09.2026       Aardvark Therapeutics
US0029421007

SAN FRANCISCO, Sept. 7, 2026 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP, a national shareholder rights firm, notifies investors in Aardvark Therapeutics, Inc. (NASDAQ: AARD) of a pending securities class action lawsuit. Investors who purchased or acquired Aardvark common stock p...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 07.09.2026       Aardvark Therapeutics
US0029421007

New York, New York--(Newsfile Corp. - September 7, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of Aardvark Therapeutics, Inc. (NASDAQ: AARD): (i) common stock pursuant and/or traceable to the registration statement and prospectus (collectively, the "Registration Statement") issued in connection with Aardv...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
So., 06.09.2026       Aardvark Therapeutics
US0029421007

NEW YORK, Sept. 6, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of Aardvark Therapeutics, Inc. (NASDAQ: AARD): (i) common stock pursuant and/or traceable to the registration statement and prospectus (collectively, the "Registration S...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
So., 06.09.2026       Aardvark Therapeutics
US0029421007

New York, New York--(Newsfile Corp. - September 6, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Aardvark Therapeutics, Inc. (NASDAQ: AARD) and certain of its officers.This lawsuit seeks to recover damages against Defendants for alleged...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
So., 06.09.2026       Aardvark Therapeutics
US0029421007

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Aardvark To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in (a) Aardvark common stock pursuant and/or traceable to the Offering Documents (defined below) issued in connection with the Compan...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
So., 06.09.2026       Aardvark Therapeutics
US0029421007

New York, New York--(Newsfile Corp. - September 6, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of Aardvark Therapeutics, Inc. (NASDAQ: AARD): (i) common stock pursuant and/or traceable to the registration statement and prospectus (collectively, the "Registration Statement") issued in connection with Aardv...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 04.09.2026       Aardvark Therapeutics
US0029421007

Shareholder rights law firm Robbins LLP reminds investors that a class action was filed on behalf of all persons and entities who purchased or otherwise acquired Aardvark Therapeutics, Inc. (NASDAQ: AARD) (a) common stock pursuant to the Company's February 13, 2025 initial public offering ("IPO") and/or (b) securities between February 13, 2025 and...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 04.09.2026       Aardvark Therapeutics
US0029421007

New York, New York--(Newsfile Corp. - September 4, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of Aardvark Therapeutics, Inc. (NASDAQ: AARD): (i) common stock pursuant and/or traceable to the registration statement and prospectus (collectively, the "Registration Statement") issued in connection with Aardv...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 04.09.2026       Aardvark Therapeutics
US0029421007

San Francisco, California--(Newsfile Corp. - September 4, 2026) - Hagens Berman Sobol Shapiro LLP, a national shareholder rights firm, notifies investors in Aardvark Therapeutics, Inc. (NASDAQ: AARD) of a pending securities class action lawsuit.Investors who purchased or acquired Aardvark common stock pursuant and/or traceable to the offering docum...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 04.09.2026       Aardvark Therapeutics
US0029421007

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Aardvark To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in (a) Aardvark common stock pursuant and/or traceable to the Offering Documents (defined below) issued in connection with the Compan...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 03.09.2026       Aardvark Therapeutics
US0029421007

SAN FRANCISCO, Sept. 3, 2026 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP, a national shareholder rights firm, notifies investors in Aardvark Therapeutics, Inc. (NASDAQ: AARD) of a pending securities class action lawsuit. Investors who purchased or acquired Aardvark common stock p...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 03.09.2026       Aardvark Therapeutics
US0029421007

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses in Aardvark to Contact Him Directly to Discuss Their OptionsNEW YORK, Sept. 3, 2026 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors of the October 13, 2026 deadline to seek the role...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 03.09.2026       Aardvark Therapeutics
US0029421007

New York, New York--(Newsfile Corp. - September 3, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of Aardvark Therapeutics, Inc. (NASDAQ: AARD): (i) common stock pursuant and/or traceable to the registration statement and prospectus (collectively, the "Registration Statement") issued in connection with Aardv...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 03.09.2026       Aardvark Therapeutics
US0029421007

New York, New York--(Newsfile Corp. - September 3, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Aardvark Therapeutics, Inc. (NASDAQ: AARD) and certain of its officers.This lawsuit seeks to recover damages against Defendants for alleged...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 03.09.2026       Aardvark Therapeutics
US0029421007

A securities class action alleges former Chief Operating Officer Bryan Jones, Ph.D. told investors in May 2025 that ARD-101 had a "very, very clean" safety profile, months before cardiac observations allegedly forced a Phase 3 pause and a full FDA clinical hold.NEW YORK, Sept. 3, 2026 /PRNewswire/ -- SueWallSt notifies investors in Aardvark Therap...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 02.09.2026       Aardvark Therapeutics
US0029421007

Lead Plaintiff Deadline October 13, 2026NEW YORK and SAN DIEGO, Sept. 2, 2026 /PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP ("Wolf Haldenstein"), a nationally recognized securities litigation law firm, announces that a securities class action lawsuit has been filed in the announces that a securities class action lawsuit has been fi...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 02.09.2026       Aardvark Therapeutics
US0029421007

A securities class action alleges Aardvark Therapeutics promised investors a "99% gut-restricted" drug with "no serious adverse events" and Phase 3 data in early 2026; instead, cardiac observations paused the HERO trial and the FDA imposed a full clinical hold.NEW YORK, Sept. 2, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP alerts investors in Aa...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 02.09.2026       Aardvark Therapeutics
US0029421007

NEW YORK, Sept. 1, 2026 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of Aardvark Therapeutics, Inc. (NASDAQ: AARD): (i) common stock pursuant and/or traceable to the registration statement and prospectus (collectively, the "Registration Statement") issued in connection with Aardvark's February 13, 2025 init...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink